Atrial Natriuretic Factor (5-27) (human)
Need Assistance?
  • US & Canada:
    +
  • UK: +

Atrial Natriuretic Factor (5-27) (human)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Peptide Inhibitors
Catalog number
BAT-014680
CAS number
98929-56-7
Molecular Formula
C97H154N34O32S3
Molecular Weight
2404.67
IUPAC Name
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoic acid
Synonyms
Atrial Natriuretic Peptide-23 (human); H-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-OH (Disulfide bridge: Cys3-Cys19); L-seryl-L-seryl-L-cysteinyl-L-phenylalanyl-glycyl-glycyl-L-arginyl-L-methionyl-L-alpha-aspartyl-L-arginyl-L-isoleucyl-glycyl-L-alanyl-L-glutaminyl-L-seryl-glycyl-L-leucyl-glycyl-L-cysteinyl-L-asparagyl-L-seryl-L-phenylalanyl-L-arginine (3->19)-disulfide
Appearance
White Lyophilized Powder
Purity
≥95%
Density
1.6±0.1 g/cm3
Sequence
SSCFGGRMDRIGAQSGLGCNSFR (Disulfide bridge: Cys3-Cys19)
Storage
Store at -20°C
Solubility
Soluble in DMSO, Water
InChI
InChI=1S/C97H154N34O32S3/c1-7-48(4)76-93(161)114-38-71(139)115-49(5)77(145)119-55(24-25-68(99)136)83(151)128-63(42-133)81(149)113-39-73(141)117-58(31-47(2)3)79(147)112-40-74(142)118-66(91(159)125-61(34-69(100)137)87(155)129-65(44-135)89(157)124-60(33-51-19-12-9-13-20-51)86(154)122-57(94(162)163)23-16-29-109-97(105)106)45-165-166-46-67(130-90(158)64(43-134)127-78(146)52(98)41-132)92(160)123-59(32-50-17-10-8-11-18-50)80(148)111-36-70(138)110-37-72(140)116-53(21-14-27-107-95(101)102)82(150)121-56(26-30-164-6)84(152)126-62(35-75(143)144)88(156)120-54(85(153)131-76)22-15-28-108-96(103)104/h8-13,17-20,47-49,52-67,76,132-135H,7,14-16,21-46,98H2,1-6H3,(H2,99,136)(H2,100,137)(H,110,138)(H,111,148)(H,112,147)(H,113,149)(H,114,161)(H,115,139)(H,116,140)(H,117,141)(H,118,142)(H,119,145)(H,120,156)(H,121,150)(H,122,154)(H,123,160)(H,124,157)(H,125,159)(H,126,152)(H,127,146)(H,128,151)(H,129,155)(H,130,158)(H,131,153)(H,143,144)(H,162,163)(H4,101,102,107)(H4,103,104,108)(H4,105,106,109)/t48-,49-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,76-/m0/s1
InChI Key
YHQWUIAQYDPQMH-YIYQVOMBSA-N
Canonical SMILES
CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)C(CO)NC(=O)C(CO)N)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCCNC(=N)N)C(=O)O)CC(C)C)CO)CCC(=O)N)C
1. Atrial natriuretic peptide: a chemoattractant of human spermatozoa by a guanylate cyclase-dependent pathway
R A Anderson Jr, K A Feathergill, R G Rawlins, S R Mack, L J Zaneveld Mol Reprod Dev. 1995 Mar;40(3):371-8. doi: 10.1002/mrd.1080400314.
Atrial natriuretic peptide (ANP), found in mammalian ovarian granulosa cells and oocytes (Kim et al., 1992, 1993), induces the human acrosome reaction (Anderson et al., 1994). The purpose of the present study was to determine whether ANP, as egg-derived peptides from sea urchins, can act as a chemoattractant to human spermatozoa. Small lengths of capillary tubing that contained different concentrations of ANP were suspended over a suspension of washed spermatozoa. The number of spermatozoa that entered the tubing was determined. More than twice the number of spermatozoa moved into the tubing that contained a maximally effective concentration of ANP, as compared with tubing that contained only medium. The concentration of ANP that produced a half-maximal effect was 0.7 nM. The effect was blocked by LY83583, an inhibitor of guanylate cyclase. ANP produced more than a twofold increase in the rate of cGMP formation, an effect that was blocked by LY83583. Human ANP (5-27), a fragment of the intact peptide, had no chemoattractant activity. These findings suggest that a specific sperm receptor exists for the chemoattractant activity of ANP that is associated with guanylate cyclase. The chemoattractant activity of ANP is independent of the presence of extracellular calcium ions and is independent of the action of ANP as a stimulus of the acrosome reaction. There is no association between the chemoattractant activity of follicular fluid and the follicular fluid concentration of ANP. These data suggest that factors besides ANP are responsible for the chemoattractant activity of follicular fluid.(ABSTRACT TRUNCATED AT 250 WORDS)
2. Direct radioimmunoassay for human atrial natriuretic peptide (hANP) and its clinical evaluation
H Jüppner, G Brabant, U Kapteina, M Kirschner, H Klein, R D Hesch Biochem Biophys Res Commun. 1986 Sep 30;139(3):1215-23. doi: 10.1016/s0006-291x(86)80307-2.
A direct radioimmunoassay for the rapid and accurate detection of human ANP from unextracted plasma is described. The sensitivity was approximately 50 pg/ml, respectively 2.5 pg/tube, the intra-assay variation 4%, and the inter-assay variation less than 12%. Rat ANP (1-28, 5-25, 5-27 and 5-28), oxydized and reduced hANP as well as plasma samples from various patients run in parallel to the 1-28 hANP standard curve. These findings imply, that the antibody primarily recognizes the mid-region (amino acids 6-25) of the intact ANP, that the C-terminal portion further increases the immunoreactivity, and that circulating plasma hANP is reliably measured. Plasma hANP ranged from 50-166 pg/ml (mean +/- SD: 98.3 +/- 44.6) in healthy individuals, there was no significant difference between samples were drawn in upright or lying position, the apparent half-life of injected hANP was 5.65 minutes. Patients with liver cirrhosis revealed significantly higher hANP levels of 244.5 +/- 173.5 pg/ml. Patients with various forms of cardiac disease had hANP concentrations ranging from 50 to 1744 pg/ml, depending at least partially on the right atrial pressure. No difference was observed if the samples were drawn from either right or left intracardial locations. Our findings with this system demonstrate that hANP is reliably measured even without prior extraction.
3. Classification of severe aortic stenosis and outcomes after aortic valve replacement
Yura Ahn, et al. Sci Rep. 2022 May 7;12(1):7506. doi: 10.1038/s41598-022-11491-3.
Aortic valve calcium scoring by cardiac computed tomographic (CT) has been recommended as an alternative to classify the AS (aortic stenosis) severity, but it is unclear that whether CT findings would have additional value to discriminate significant AS subtypes including high gradient severe AS, classic low-flow, low gradient (LF-LG) AS, paradoxical LF-LG AS, and moderate AS. In this study, we examined the preoperative clinical and cardiac CT findings of different subtypes of AS in patients with surgical aortic valve replacement (AVR) and evaluated the subtype classification as a factor affecting post-surgical outcomes. This study included 511 (66.9 ± 8.8 years, 55% men) consecutive patients with severe AS who underwent surgical AVR. Aortic valve area (AVA) was obtained by echocardiography (AVAecho) and by CT (AVACT) using each modalities measurement of the left ventricular outflow tract. Patients with AS were classified as (1) high-gradient severe (n = 438), (2) classic LF-LG (n = 18), and (3) paradoxical LF-LG (n = 55) based on echocardiography. In all patients, 455 (89.0%) patients were categorized as severe AS according to the AVACT. However, 56 patients were re-classified as moderate AS (43 [9.8%] high-gradient severe AS, 5 [27.8%] classic LF-LG AS, and 8 [14.5%] paradoxical LF-LG AS) by AVACT. The classic LF-LG AS group presented larger AVACT and aortic annulus than those in high-gradient severe AS group and one third of them had AVACT ≥ 1.2 cm2. After multivariable adjustment, old age (hazard ratio [HR], 1.04, P = 0.049), high B-type natriuretic peptide (BNP) (HR, 1.005; P < 0.001), preoperative atrial fibrillation (HR, 2.75; P = 0.003), classic LF-LG AS (HR, 5.53, P = 0.004), and small aortic annulus on CT (HR, 0.57; P = 0.002) were independently associated with major adverse cardiac and cerebrovascular events (MACCE) after surgical AVR.
Online Inquiry
Verification code
Inquiry Basket